Global Personalized Medicines Strategic Business R

Dublin, May 23, 2018 (GLOBE NEWSWIRE) -- The "Personalized Medicines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Segments:

• Targeted Therapeutics
• Tests & Lab Services

The report profiles 87 companies including many key and niche players such as:

• Abbott Molecular, Inc. (USA)
• Beckman Coulter Genomics (USA)
• bioMrieux SA (France)
• Bristol-Myers Squibb Company (USA)
• Dako Denmark A/S (Denmark)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline plc. (UK)
• Hologic, Inc. (USA)
• Lab 21 Limited (UK)
• Macrogen, Inc. (Korea)
• NeoGenomics Laboratories, Inc. (USA)
• Novartis AG (Switzerland)
• QIAGEN NV (The Netherlands)
• Rosetta Genomics Ltd (Israel)
• Thermo Fisher Scientific Inc. (USA)

Key Topics Covered:

1. INDUSTRY OVERVIEW Access to Valuable Genetic Information Ushers Transformation in Medicine Market Outlook Adoption of Personalized Medicines A Peek into Developed and Developing Economies Increasing Market Availability of Personalized Medicines Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area Constraints in Traditional Approach to Treatment Creates Need and Demand for Personalized Medicine Economics of Personalized Medicine Is Emergence of Personalized Medicine Signalling the End of Blockbusters? 2. MARKET DRIVERS AND RESTRAINTS Growth Drivers in a Gist Key Market Restraints Increasing Incidence and Prevalence of CDDs: A Major Growth Driver Oncology A Major Application Market Diagnosed Cases of Cancer on the Rise World Cancer Statistics: Incidence and Mortality Data Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market Growing Importance of Personalized Drugs for Cancer Treatment Ballooning Global Population Offers Significant Growth Opportunities Aging Global Population Drives Personalized Medicines Increasing Healthcare Spending in Emerging Markets Changing Patients' Trends Drive Personalized Medicine Technological Advancements and Consumer Push to Drive Personalized Medicine 3. MARKET TRENDS & ISSUES Minimizing Adverse Events A Major Benefit of Personalized Medicines Personalized Medicines Brings Disease Prevention Closer to Reality Ability to Manage Healthcare Costs Piques Industry and Government Alike Potential to Uncover Additional Prospective Targets A Major Benefit in Pursuit Elimination of Invasive Tests Attracts Patients and Doctors towards Molecular Test-based Personalized Medicines Genomics to Dictate Advancement of Personalized Medicines Companion Diagnostics Drive Personalized Medicine Biomarkers as Companion Diagnostics Personalized Medicines Help Reducing R&D Costs Personalized Medicine A Corporate Growth Strategy Development Pipeline Reveals Promising Picture for Personalized Medicine Advancements in Biomedical Imaging to Enhance Personalized Medicines Increasing Use of Personalized Medicines Drives Genetic Testing Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market Next-Generation Sequencing A Giant Leap in Genome Sequencing Single Nucleotide Polymorphism (SNP) Making Advancements in Personalized Medicine Personalized Medicine Goes Beyond DNA Analysis Combination Approaches May Mark Future Endeavors Need for New Designs in Clinical Trials Emerges in Therapies for Rare Cancers Immunotherapy for Cancers A Potential Breakthrough in the Sector Personalized Medicine Industry Inundated with Data Advanced Computing Technologies The Need of The Hour to Analyze Large Data Artificial Intelligence Revolutionizing Personalized Medicine Challenges Aplenty for Precision Medicine Lack of Clinically Useful Diagnostic Tests Growth Dampener Pricing and Value Dilemma Haunts Personalized Medicines Bedside Biopharmaceutical Production to Dramatically Reduce Cost of Personalized Medicine 4. PRODUCT OVERVIEW Personalized Medicine Benefits of Personalized Medicines Few Applications of Personalized Medicine Colorectal Cancer Blood Clots Breast Cancer Diagnostics in Personalized Medicine Genetic Tests Companion Diagnostics Genetic Testing Types of Genetic Testing Prenatal Diagnosis Cancer Testing Carrier Identification Newborn Screening Predictive Testing Pre-Symptomatic Testing Cytogenetic Tests Proteomics: A Critical Drug Discovery Tool Proteomics and Genomics: A Comparison 5. PRODUCT INTRODUCTIONS AND APPROVALS Somalogic Teams Up with Leeds University for Personalized Medicines University of Tokyo Sings Alliances for Developing Personalized Cancer Vaccine Helomics and Ariel Ink Service Agreement to Commercialize PancreasDx Genomic Assay Skyline Licenses Illumina's MiSeqDx NGS Platform Genoptix to Acquire Rosetta DTU Bioinformatics Inks MoU with A*STAR Bayer Inks Agreement with Loxo Oncology for Investigational Personalized Cancer Therapies HealthSystem Joins Hands with Ambry Genetics to Advancing Precision Medicine Development Invitrocue Establishes Joint Lab with A*STAR to Develop Personalized Medicine OneOme and ProZed Partner to Bring Personalized Medicine to Canada Insilico Medicine Launches ALS.AI Platform Sysmex to Acquire Oxford Gene Technology CVI to Partner with Panaceutics Panaceutics Acquires Triangle Compounding Pharmacy Acobiom Secures Funding from Bpifrance for OncoSNIPE Project Genospace Merges with Sarah Cannon QNRF and QGP Launch Second Cycle of Path Towards Personalized Medicine VieCure and Avera Team Up for Personalized Medicine PierianDx Acquires Tute Genomics iConquerMS Launches REAL MS Study IntelliCyt Collaborates with Notable Labs to Advance Predictive Personalized Medicine Platform Thermo Fisher Partners with West China Hospital to Develop Precision Medicine Swagene Introduces Personalized Medicine for Blood Cancer in Children Macrogen Inks Joint Research Agreement with National Cancer Center Korea Contextual Genomics Launches Phase II of Find It Genomics Test 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 87 (including Divisions/Subsidiaries 95)

• The United States (64)
• Canada (4)
• Japan (3)
• Europe (17)
  • France (5)
  • Germany (3)
  • The United Kingdom (3)
  • Rest of Europe (6)
• Asia-Pacific (Excluding Japan) (6)
• Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/2...lobal?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics